Prosecution Insights
Last updated: November 20, 2026
Application No. 19/487,114

METHOD AND APPARATUS FOR PROVIDING TREATMENT-RELATED PREDICTION INFORMATION OF ALZHEIMER'S DISEASE

Non-Final OA §101§102§112
Filed
Jan 06, 2026
Priority
May 24, 2023 — RE 10-2023-0067231 +1 more
Examiner
DAVIS, AMELIE R
Art Unit
3793
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Neuroxt Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
308 granted / 474 resolved
-5.0% vs TC avg
Strong +34% interview lift
Without
With
+33.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
40 currently pending
Career history
521
Total Applications
across all art units

Statute-Specific Performance

§101
9.2%
-30.8% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
38.7%
-1.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 474 resolved cases

Office Action

§101 §102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3, 10 - 13, 17, and 19 - 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 is indefinite because it is unclear what method step or material modification thereof is intended by “the first score remains the same or increases as the amount of accumulated tau protein in the first region of the subject's brain increases, and the second score remains the same or increases as the amount of accumulated tau protein in the second region of the subject's brain increases”. It is unclear if the claim requires a method step of ‘increasing the amount of accumulated tau protein in the first region of the subject's brain’ and keeping the first score the same or increasing it’, for example. Claim 10 is indefinite because there is insufficient antecedent basis for “the golden time”. The limitation has not been recited in the dependency chain of claim 10. It is unclear what is being referred to. Claim 12 is indefinite because “second time” is improper ordinal numbering, as no first time has been recited in the dependency chain of claim 12. It is unclear how many times are required. Similar logic applies to the “third” and “fourth” times, as well as the “second threshold”. Claim 17 is indefinite because “third threshold value” is improper ordinal numbering, as no second threshold value has been recited in the dependency chain of claim 17. It is unclear how many thresholds are required. Claim 19 is indefinite because “second threshold value” is improper ordinal numbering, as no first threshold value has been recited in the dependency chain of claim 19. It is unclear how many thresholds are required. Claim 20 is indefinite because it is unclear what is meant by “based on the amount of accumulated tau protein in the first region of the subject's brain based on the amount of accumulated tau protein in the first region of the subject's brain”. The logic appears to be circular, rendering the require basis unclear. For the purposes of examination, the limitation will be interpreted as containing superfluous repetitive text. Note: dependent claims that are listed in the rejection header above as being rejected while not having been specifically addressed are rejected by virtue of dependency. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim 20 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claim is directed to a computer program, which is software per se. Examiner suggests amending the claim to be directed to a non-transitory computer-readable recording medium that stores the program. Claims 1 - 21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a mental-process type abstract idea) without significantly more. Independent claim 1: With regard to Step 1, the claim is directed to one of the four statutory categories of invention, i.e., a method of providing treatment-related prediction information for Alzheimer's disease. With regard to Step 2A: Prong 1, the claim recites limitations directed towards: determining an amount of accumulated tau protein in a first region of the subject's brain based on the scan image; and calculating a first score associated with a need for treatment of Alzheimer's disease in the subject based on the amount of accumulated tau protein in the first region of the subject's brain. As drafted, these limitations amount to nothing more than steps that can practically be performed in the human mind and/or with the aid of pen/paper. Therefore, the limitations recite a mental-process type abstract idea. See MPEP 2106.04(a)(2). With regard to Step 2A: Prong 2, the claim recites additional elements involving: receiving a brain scan image of a subject, which is extra-solution activity (i.e., data gathering); and that a processor performs the mental step, which amounts to no more than an instruction to implement the judicial exception on a computer. Therefore, the recited additional elements do not, either individually or as a whole, integrate the judicial exception into a practical application. With regard to Step 2B, as explained above, the additional limitations are directed towards extra-solution activity and an instruction to implement the judicial exception on a computer. Therefore, when considered separately and in combination, the additional limitations do not result in the claim, as a whole, amounting to significantly more than the judicial exception. Independent claim 20: The claim is directed to a judicial exception (i.e., a mental-process type abstract idea) without significantly more for reasons similar to those of claim 1. Independent claim 21: With regard to Step 1, the claim is directed to one of the four statutory categories of invention, i.e., an apparatus. With regard to Step 2A: Prong 1, the claim recites limitations directed towards: determining an amount of accumulated tau protein in a first region of the subject's brain based on the scan image; and calculating a first score associated with a need for treatment of Alzheimer's disease in the subject based on the amount of accumulated tau protein in the first region of the subject's brain. As drafted, these limitations amount to nothing more than steps that can practically be performed in the human mind and/or with the aid of pen/paper. Therefore, the limitations recite a mental-process type abstract idea. See MPEP 2106.04(a)(2). With regard to Step 2A: Prong 2, the claim recites additional elements involving: receiving a brain scan image of a subject, which is extra-solution activity (i.e., data gathering); a memory, and a processor that performs the mental step, which amounts to no more than an instruction to implement the judicial exception on a computer; a communication module, which is generic hardware for extra-solution activity. Therefore, the recited additional elements do not, either individually or as a whole, integrate the judicial exception into a practical application. With regard to Step 2B, as explained above, the additional limitations are directed towards extra-solution activity and an instruction to implement the judicial exception on a computer. Therefore, when considered separately and in combination, the additional limitations do not result in the claim, as a whole, amounting to significantly more than the judicial exception. Dependent claims: claim 2 recites further calculations that read on a mental step. The claim also recites that the first region and the second region are different regions, which merely limits the judicial exception to a particular technological environment. claim 3 recites “the first score remains the same or increases as the amount of accumulated tau protein in the first region of the subject's brain increases, and the second score remains the same or increases as the amount of accumulated tau protein in the second region of the subject's brain increases” which encompasses a law of nature and/or natural phenomenon. Alternatively the limitations merely limit the judicial exception to a particular technological environment. claims 4 - 11 and 17 - 19 recite further calculations, determinations, predictions, and/or identifications that read on mental steps. claims 12 - 13 recite details of the calculations, which merely further limit the judicial exceptions and do not prevent the steps from being performed mentally and/or with the aid of pen/paper claims 14 - 16 recite characterizations that merely limit the judicial exception to a particular technological environment. Therefore, when considered separately and in combination, the additional limitations do not integrate the judicial exception into a practical application, or result in the dependent claims amounting to significantly more than the judicial exception. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 - 21 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Seeley et al. (WO 2022/072738, of record). Regarding claims 1, 20, and 21, Seeley shows a system configured to perform a method of providing treatment-related prediction information for Alzheimer's disease. The system comprises a communication module (communication interfaces, page 74, bottom par.) and a processor (computer, page 74, bottom par.) configured by instructions in memory to: receive a brain scan image of a subject (imaging a brain of the subject, claim 1), determine an amount of accumulated tau protein in a first region of the subject's brain based on the scan image (analyzing tau protein deposition in at least one region within the brain of the subject, claim 1), and calculate a first score associated with a need for treatment of Alzheimer's disease in the subject based on the amount of accumulated tau protein in the first region of the subject's brain (“first normalized score … tau protein deposition in a first region of the brain”, claim 1). Regarding claim 2, Seeley discloses the claimed invention substantially as noted above. Seeley further shows determining an amount of accumulated tau protein in a second region of the subject's brain based on the scan image; and calculating a second score associated with efficacy of the treatment of Alzheimer's disease in the subject based on the amount of accumulated tau protein in the second region (second region of the brain of the subject, claim 1), wherein the first region and the second region are different regions (plurality of regions of the brain of the subject, claim 3). Regarding claim 3, Seeley discloses the claimed invention substantially as noted above. Seeley further shows the first score remains the same or increases as the amount of accumulated tau protein in the first region of the subject's brain increases, and the second score remains the same or increases as the amount of accumulated tau protein in the second region of the subject's brain increases (see calculations on page 4). Regarding claim 4, Seeley discloses the claimed invention substantially as noted above. Seeley further shows calculating an overall score associated with the treatment of Alzheimer's disease in the subject based on the first score and the second score (“Based on the calculated first and second normalized scores, the methods of the disclosure make it possible to assess the suitability of a given AD therapy”, page 37, bottom par. - the combined consideration of the first and second scores is interpreted as an “overall score”). Regarding claim 5, Seeley discloses the claimed invention substantially as noted above. Seeley further shows determining whether to treat Alzheimer's disease in the subject or at least one type of treatment based on at least one of the first score, the second score, or the overall score (“Based on the calculated first and second normalized scores, the methods of the disclosure make it possible to assess the suitability of a given AD therapy”, page 37, bottom par.). Regarding claims 6 - 7 and 10 - 11, Seeley discloses the claimed invention substantially as noted above. Seeley further shows estimating a start point of a golden time Alzheimer's disease in the subject based on the first score and remaining time until the golden time ends (“critical period … therapeutic window”, page 111, middle). Regarding claims 8 - 9, Seeley discloses the claimed invention substantially as noted above. Seeley further shows calculating a first time interval between a first time corresponding to the amount of accumulated tau protein in the first region and a second time at which the amount of accumulated tau protein reaches a predetermined first threshold value, on a first path representing a predicted value of the amount of accumulated tau protein in the first region over time; and calculating the first score based on the first time interval, wherein the first path is determined based on a data set associated with the amount of accumulated tau protein in the first region over time for the subject's brain and a brain of each of a plurality of other subjects. (see page 4, and claims 1 and 9 - 10). Regarding claims 12 - 13, Seeley discloses the claimed invention substantially as noted above. Seeley further shows calculating a second time interval between a third time corresponding to the amount of accumulated tau protein in the second region of the subject's brain and a fourth time at which the amount of accumulated tau protein reaches a predetermined second threshold value, on a second path representing a predicted value of the amount of accumulated tau protein in the second region over time; and calculating the second score based on the second time interval, wherein the second path is determined based on a data set associated with the amount of accumulated tau protein in the second region over time for the subject's brain and a brain of each of a plurality of other subjects (see page 4, and claims 1 and 9 - 10). Regarding claim 14, Seeley discloses the claimed invention substantially as noted above. Seeley further shows the subject is a patient in whose brain there is determined to be an accumulation of beta-amyloid protein greater than or equal to a predetermined threshold value (threshold, claim 4). Regarding claims 15 - 16, Seeley discloses the claimed invention substantially as noted above. Seeley further shows the first region is an entorhinal cortex (EC) region (claim 15) and the second region is an inferior temporal gyrus (ITG) region (claim 16). Regarding claims 17 - 19, Seeley discloses the claimed invention substantially as noted above. Seeley further shows in response to determining that the overall, first, and second scores are greater than a predetermined threshold value (“Based on the calculated first and second normalized scores, the methods of the disclosure make it possible to assess the suitability of a given AD therapy … threshold …”, page 37, bottom par. - the combined consideration of the first and second scores is interpreted as an “overall score”), identifying that the subject is within a golden time for which the subject is expected to respond to an amyloid-modulating treatment as the treatment of Alzheimer's disease (“critical period … therapeutic window”, page 111, middle), identifying that the subject is expected to respond to Alzheimer's prevention therapy, and identifying that the subject is expected to respond to combination treatment including amyloid-modulating treatment and tau modulating treatment, as the treatment of Alzheimer's disease (pages 6 - 9). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMELIE R DAVIS whose telephone number is (571)270-7240. The examiner can normally be reached Monday-Friday, 9:30 - 6:00 PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Pascal Bui-Pho can be reached at (571)272-2714. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMELIE R DAVIS/Primary Examiner, Art Unit 3798
Read full office action

Prosecution Timeline

Jan 06, 2026
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12791476
MULTIPLE LIGHT PATHS ARCHITECTURE AND OBSCURATION METHODS FOR SIGNAL AND PERFUSION INDEX OPTIMIZATION
2y 2m to grant Granted Nov 10, 2026
Patent 12778442
Method And Apparatus For Moving A Reference Device
2y 7m to grant Granted Nov 03, 2026
Patent 12758353
A Fiducial Marker Set, A Method Of Determining A Position Of The Same And A Control System
2y 9m to grant Granted Oct 13, 2026
Patent 12758145
CONTACTLESS SLEEP DETECTION AND DISTURBANCE ATTRIBUTION FOR MULTIPLE USERS
2y 3m to grant Granted Oct 13, 2026
Patent 12751694
ULTRASONIC DIAGNOSTIC APPARATUS
2y 8m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
98%
With Interview (+33.5%)
3y 6m (~2y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 474 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month